You should use this information to not only fend for yourself, but to more accurately guide trainees into a richly rewarding specialty that pays well and has many distinctions to boast of, including high science, hands-on patient interactions and long-term relationships, great hours, lifestyle and family friendly careers. Our field is in desperate need of high quality, problem-solving practitioners.

The New England Journal of Medicine has reported the results of a large clinical trial demonstrating the efficacy of ustekinumab (Stelara) in treating patients with active Crohn's disease (CD). (Citation source http://buff.ly/2gsSNcs)

It is well known that ANCA-associated vasculitides can be hard to control and relapses are common. The choice of maintenance therapy is rather limited and therapies are not always effective.

Dr. Philip Mease, MD presented the long-term efficacy and safety data for secukinumab in psoriatic arthritis (PsA) at the ACR Annual meeting in Washington, DC.

Some big highlights from Tuesday at the 2016 ACR/ARHP annual meeting included the PRECISION trial, EXXELERATE trial and the new anti-IL-23 in psoriatic arthritis.

The PRECISION trial was published this week in the NEJM, presented at the Cardiology meetings in New Orleans, and presented today by Dr. Daniel Solomon at the 2016 ACR annual meeting in Washington, D.C. (citation source http://buff.ly/2fUmoqO)

New treatment options for psoriatic arthritis continue to be explored at this year’s ACR/ARHP Annual Meeting in Washington, DC. Guselkumab (GUS) is a fully human monoclonal antibody against the p19 subunit of IL-23.  

It is well known that ANCA-associated vasculitides can be hard to control and relapses are common. The choice of maintenance therapy is rather limited and therapies are not always effective.

On Monday, November 13, there were two new presentations at the annual ACR 2016 meeting on new biologics seeking approval for use in polyarticular juvenile arthritis.

The PRECISION study will be presented on Tuesday, November 15, 2016 by Dr. Elaine Husni from the Cleveland Clinic. This report brings to a climax the controversy ignited by the February 2005 3 day FDA Arthritis Advisory Committee review of the safety of the blockbuster COX-2 inhibitors, celecoxib, rofecoxib, and valdecoxib.

At this years 2016 ACR/ARHP Annual Meeting Pfizer will presen 20 abstracts, mostly centering around its JAK inhibitor tofacitinib (Xeljanz). They will also present the results of their Phase 3 OPAL studies of tofacitinib in patients with psoriatic arthritis.

Eli Lilly & Co. has multiple presentations planned for the upcoming Annual meeting of the ACR/ARHP in Washington starting on Sunday, November 13th.

Janssen has announced the listings for it's presentations at the upcoming annual ACR/ARHP 2016 meeting in Washington.

CreakyJoints will be presenting 5 Posters at the 2016 ACR/AHRP Annual Meeting. At the meeting they will also announce the publication of first-ever Rheumatoid Arthritis Patient Guidelines. 

At the upcoming 2016 ACR/ARHP Annual Meeting, Genentech will present 15 oral presentations from 17 abstracts relating to the use of tocilizumab and rituximab in a number of varied autoimmune conditions.

Crescendo Bioscience has announced that it will have 4 poster presentations at the American College of Rheumatology 2016 Annual Meeting next week.

Etanercept (Enbrel) received FDA approval Friday for use in children with moderate to severe, chronic plaque psoriasis.  Previously approved for adults with plaque psoriasis the new indication will be for chronic plaque psoriasis for those over age 4 years.

Dr. Jack Cush reviews highlights and reports from this week on RheumNow.com, including drug-induced cutaneous lupus, pediatric lupus being worse, new gout drug SEL-12, Gut microbiome and IgA plasmablasts, and the weakly-received new ACP guidelines on gout.

ACP released clinical practice guidelines for the diagnosis and management of gout. Interestingly, these are not always aligned with the 2012 ACR gout guidelines.